tbuckley/cabot-search huggingface dataset:
No evidence of leptin mediating the effect of body mass index on hand pain and its duration in the Chingford 1000 Women Study: original research supplementing the study by Gløersen et al
Authors: Romain S. Perera, Malvika Gulati, Karishma Shah, Deborah J. Hart, Tim D. Spector, Nigel K. Arden, Maja R. Radojčić
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The impact of VEGF on cancer metastasis and systemic disease
Authors: Yunlong Yang, Yihai Cao
Journal: Seminars in Cancer Biology (2022)

Metastasis is the leading cause of cancer-associated mortality and the underlying mechanisms of cancer metastasis remain elusive. Both blood and lymphatic vasculatures are essential structures for mediating distal metastasis. The vasculature plays multiple functions, including accelerating tumor growth, sustaining the tumor microenvironment, supplying growth and invasive signals, promoting metastasis, and causing cancer-associated systemic disease. VEGF is one of the key angiogenic factors in tumors and participates in the initial stage of tumor development, progression and metastasis. Consequently, VEGF and its receptor-mediated signaling pathways have become one of the most important therapeutic targets for treating various cancers. Today, anti-VEGF-based antiangiogenic drugs (AADs) are widely used in the clinic for treating different types of cancer in human patients. Despite nearly 20-year clinical experience with AADs, the impact of these drugs on cancer metastasis and systemic disease remains largely unknown. In this review article, we focus our discussion on tumor VEGF in cancer metastasis and systemic disease and mechanisms underlying AADs in clinical benefits.
COMPLICATIONS AND FAILURE MODES OF THE TURNPIKE CATHETERS: INSIGHTS FROM MAUDE DATABASE
Authors: Rashid Alhusain, Adnan Halboni, Abdalaziz Awadelkarim, John Dayco, Ahmed Ahmed, Mohamed Elhussein, Mohamed Zghouzi, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2022)
False-Positive 131I Uptake After Transareola Endoscopic Thyroidectomy in a Patient With Papillary Thyroid Carcinoma
Authors: Anbo Wang, Wenhui Fu, Ying Deng, Limeng He, Wei Zhang
Journal: Clinical Nuclear Medicine (2022)

Abstract False-positive 131 I accumulation in patients with thyroid carcinoma could be due to various etiologies. Herein, we reported a case of papillary thyroid carcinoma in a 36-year-old woman. She underwent a 131 I radiotherapy after a transareola endoscopic total thyroidectomy. 131 I scintigraphy showed a high uptake in the thyroid bed. Surprisingly, increased activity was also noted in the right areola area. This activity corresponding to the entry site of endoscope revealed on the following SPECT/CT.
secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics
Authors: Harish Kumar, Suman Mazumder, Sayak Chakravarti, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji Kumar, Linda B Baughn, Brian G Van Ness, Amit Kumar Mitra
Journal: Blood Cancer Journal (2022)

Abstract Multiple myeloma, the second-most common hematopoietic malignancy in the United States, still remains an incurable disease with dose-limiting toxicities and resistance to primary drugs like proteasome inhibitors (PIs) and Immunomodulatory drugs (IMiDs). We have created a computational pipeline that uses pharmacogenomics data-driven optimization-regularization/greedy algorithm to predict novel drugs (“secDrugs”) against drug-resistant myeloma. Next, we used single-cell RNA sequencing (scRNAseq) as a screening tool to predict top combination candidates based on the enrichment of target genes. For in vitro validation of secDrugs, we used a panel of human myeloma cell lines representing drug-sensitive, innate/refractory, and acquired/relapsed PI- and IMiD resistance. Next, we performed single-cell proteomics (CyTOF or Cytometry time of flight) in patient-derived bone marrow cells (ex vivo), genome-wide transcriptome analysis (bulk RNA sequencing), and functional assays like CRISPR-based gene editing to explore molecular pathways underlying secDrug efficacy and drug synergy. Finally, we developed a universally applicable R-software package for predicting novel secondary therapies in chemotherapy-resistant cancers that outputs a list of the top drug combination candidates with rank and confidence scores. Thus, using 17AAG (HSP90 inhibitor) + FK866 (NAMPT inhibitor) as proof of principle secDrugs, we established a novel pipeline to introduce several new therapeutic options for the management of PI and IMiD-resistant myeloma.
THE EFFECT OF VASOPRESSIN AND METHYLPREDNISOLONE ON RETURN OF SPONTANEOUS CIRCULATION IN PATIENTS WITH IN-HOSPITAL CARDIAC ARREST: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Basel Abdelazeem, Ahmed K. Awad, Nouraldeen Manasrah, Merihan A. Elbadawy, Soban Ahmad, Pramod K. Savarapu, Arvind Kunadi
Journal: Journal of the American College of Cardiology (2022)
SERIAL ASSESSMENT OF BIOMARKERS AND THE RISK OF HEART FAILURE IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ENGAGE AF-TIMI 48 TRIAL
Authors: Kazuma Oyama, Robert P. Giugliano, Christian Ruff, David Berg, Minao Tang, Hans Joachim Lanz, Elliott M. Antman, Eugene Braunwald, David A. Morrow
Journal: Journal of the American College of Cardiology (2022)
Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth
Authors: Gregory Gydush, Erica Nguyen, Jin H. Bae, Timothy Blewett, Justin Rhoades, Sarah C. Reed, Douglas Shea, Kan Xiong, Ruolin Liu, Fangyan Yu, Ka Wai Leong, Atish D. Choudhury, Daniel G. Stover, Sara M. Tolaney, Ian E. Krop, J. Christopher Love, Heather A. Parsons, G. Mike Makrigiorgos, Todd R. Golub, Viktor A. Adalsteinsson
Journal: Nature Biomedical Engineering (2022)
Association of Changes in Medicaid Dental Benefits With Localized Diagnosis of Oral Cavity Cancer
Authors: Lulia A. Kana, Evan M. Graboyes, Daniel Quan, Jordan Grauer, Nosayaba Osazuwa-Peters, Justin M. Barnes, John D. Cramer
Journal: JAMA Oncology (2022)

This cohort study uses data from the Surveillance, Epidemiology, and End Results database to examine the association between changes in Medicaid dental insurance coverage in California between 2009 and 2014 and rates of localized oral cavity cancer diagnoses.
ASSOCIATION OF PROPHYLACTIC DISTAL PERFUSION CANNULATION WITH MORTALITY IN PATIENTS RECEIVING VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION
Authors: Hyeok-Hee Lee, Woo Jin Jang, Chul-Min Ahn, Woo Jung Chun, Ju Hyeon Oh, Yong Hwan Park, Seung-Jun Lee, Sung-Jin Hong, Jeong Hoon Yang, Jung-Sun Kim, Hyeon Chang Kim, Byeong-Keuk Kim, Cheol Woong Yu, Hyun-Joong Kim, Jang-Whan Bae, Young-Guk Ko, Donghoon Choi, Hyeon-Cheol Gwon, Myeong-Ki Hong, Yangsoo Jang
Journal: Journal of the American College of Cardiology (2022)
REAL-TIME CMR IMAGING FOR NON-INVASIVE CHARACTERISATION OF HFPEF: MEDIUM-TERM OUTCOMES OF THE HFPEF STRESS TRIAL
Authors: Sören Jan Backhaus, Simon F. Rösel, Alexander Schulz, Torben Lange, Kristian Hellenkamp, Roman Gertz, Rolf K. Wachter, Michael Steinmetz, Shelby Kutty, Uwe Raaz, Tim Friede, Tim Seidler, Martin Uecker, Gerd Hasenfuss, Andreas Schuster
Journal: Journal of the American College of Cardiology (2022)
IDENTIFYING BASELINE TOP PREDICTORS OF LIPID-RICH NECROTIC CORE BY MACHINE LEARNING IN PSORIASIS
Authors: Christin G. Hong, Haiou Li, Nidhi Patel, Philip M. Parel, Grigory A. Manyak, Alex R. Berg, Ross O’Hagan, Elizabeth Florida, Justin Rodante, Heather Teague, Martin Peter Playford, Alexander V. Sorokin, Colin O. Wu, Marcus Chen, Mohsin S. Jafri, Eric Munger, Nehal N. Mehta
Journal: Journal of the American College of Cardiology (2022)
Data-driven testing program improves detection of COVID-19 cases and reduces community transmission
Authors: Steven J. Krieg, Carolina Avendano, Evan Grantham-Brown, Aaron Lilienfeld Asbun, Jennifer J. Schnur, Marie Lynn Miranda, Nitesh V. Chawla
Journal: npj Digital Medicine (2022)

COVID-19 remains a global threat in the face of emerging SARS-CoV-2 variants and gaps in vaccine administration and availability. In this study, we analyze a data-driven COVID-19 testing program implemented at a mid-sized university, which utilized two simple, diverse, and easily interpretable machine learning models to predict which students were at elevated risk and should be tested. The program produced a positivity rate of 0.53% (95% CI 0.34-0.77%) from 20,862 tests, with 1.49% (95% CI 1.15-1.89%) of students testing positive within five days of the initial test-a significant increase from the general surveillance baseline, which produced a positivity rate of 0.37% (95% CI 0.28-0.47%) with 0.67% (95% CI 0.55-0.81%) testing positive within five days. Close contacts who were predicted by the data-driven models were tested much more quickly on average (0.94 days from reported exposure; 95% CI 0.78-1.11) than those who were manually contact traced (1.92 days; 95% CI 1.81-2.02). We further discuss how other universities, business, and organizations could adopt similar strategies to help quickly identify positive cases and reduce community transmission.
A 68Ga-FAPI-46 PET/CT Imaging Pitfall in Assessing Residual Gastric Cancer Early After Chemotherapy
Authors: Siri af Burén, Thuy A. Tran, Fredrik Klevebro, Maria Holstensson, Rimma Axelsson
Journal: Clinical Nuclear Medicine (2022)

After neoadjuvant chemotherapy, preoperative imaging with 68Ga-FAPI-46 PET/CT showed a similar level of tracer uptake at the location of the primary tumors in 2 patients with gastric cancer. Postoperative histopathology revealed residual malignant cells only in one of the patients, whereas the elevated FAPI uptake in the other patient correlated to an inflammatory reaction and fibrosis. With this case, we would like to highlight that an increased FAPI uptake in inflammatory and fibrotic tissue early after chemotherapy may represent a potential interpretation pitfall. Further studies evaluating the clinical application of FAPI-PET in assessing residual cancer tissue are warranted.
Gattaca: Base-Pair Resolution Mutation Tracking for Somatic Evolution Studies using Agent-based Models
Authors: Ryan O. Schenck, Gabriel Brosula, Jeffrey West, Simon Leedham, Darryl Shibata, Alexander R.A. Anderson
Journal: Molecular Biology and Evolution (2022)

Research over the past two decades has made substantial inroads into our understanding of somatic mutations. Recently, these studies have focused on understanding their presence in homeostatic tissue. In parallel, agent-based mechanistic models have emerged as an important tool for understanding somatic mutation in tissue; yet no common methodology currently exists to provide base-pair resolution data for these models. Here, we present Gattaca as the first method for introducing and tracking somatic mutations at the base-pair resolution within agent-based models that typically lack nuclei. With nuclei that incorporate human reference genomes, mutational context, and sequence coverage/error information, Gattaca is able to realistically evolve sequence data, facilitating comparisons between in silico cell tissue modeling with experimental human somatic mutation data. This user-friendly method, incorporated into each in silico cell, allows us to fully capture somatic mutation spectra and evolution.
THE IMPACT OF LIFESTYLE AND SOCIOECONOMIC FACTORS ON NON-STEROIDAL ANTI-INFLAMMATORY DRUG INITIATION IN THE GENERAL POPULATION: A COHORT STUDY
Authors: Kasper Bonnesen, Vera Ehrenstein, Ola Ekholm, Lars Pedersen, Henrik T. Sørensen, Morten Schmidt
Journal: Journal of the American College of Cardiology (2022)
Endoscopic findings of paraduodenal or groove pancreatitis
Authors: Pedro López-Muñoz, Vicente Lorenzo-Zúñiga, Noelia Alonso-Lázaro, María García-Campos, Lidia Argüello, Marco Bustamante-Balén, Vicente Pons-Beltrán
Journal: Endoscopy (2022)

Paraduodenal pancreatitis is an uncommon type of focal chronic pancreatitis characterized by scarring of the pancreaticoduodenal space. The possible pathogenesis includes disconnection or impairment of communication between the ducts of Santorini and Wirsung [1]. The clinical presentation of paraduodenal pancreatitis can be similar to that of pancreatic head carcinoma, so its diagnosis and treatment is usually a challenge. Other previous entities with similar clinicopathological features, such as duodenal cystic dystrophy, duodenal wall cyst, or groove pancreatitis, should no longer be used [2] [3].
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Authors: Alexandra Schäfer, David R. Martinez, John J. Won, Rita M. Meganck, Fernando R. Moreira, Ariane J. Brown, Kendra L. Gully, Mark R. Zweigart, William S. Conrad, Samantha R. May, Stephanie Dong, Rao Kalla, Kwon Chun, Venice Du Pont, Darius Babusis, Jennifer Tang, Eisuke Murakami, Raju Subramanian, Kimberly T. Barrett, Blake J. Bleier, Roy Bannister, Joy Y. Feng, John P. Bilello, Tomas Cihlar, Richard L. Mackman, Stephanie A. Montgomery, Ralph S. Baric, Timothy P. Sheahan
Journal: Science Translational Medicine (2022)

The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and treatment options remain limited. In addition, the emergence of SARS-CoV-2 variants of concern, with their potential to escape neutralization by therapeutic monoclonal antibodies, emphasizes the need to develop second-generation oral antivirals targeting highly conserved viral proteins that can be rapidly deployed to outpatients. Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase. GS-621763 exhibited antiviral activity against SARS-CoV-2 in lung cell lines and two different human primary lung cell culture systems. GS-621763 was also potently antiviral against a genetically unrelated emerging coronavirus, Middle East respiratory syndrome CoV (MERS-CoV). The dose-proportional pharmacokinetic profile observed after oral administration of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2. Therapeutic GS-621763 administration reduced viral load and lung pathology; treatment also improved pulmonary function in COVID-19 mouse model. A direct comparison of GS-621763 with molnupiravir, an oral nucleoside analog antiviral that has recently received EUA approval, proved both drugs to be similarly efficacious in mice. These data support the exploration of GS-441524 oral prodrugs for the treatment of COVID-19.
HSR22-134: Outcomes of Patients who Received Radiation Therapy for Brain Metastases From Gynecologic Malignancies
Authors: Eric Chen, Todd Aquino-Michaels, Sadhvi Batra, Riley Lochner, Anthony Rizzo, Ravi Kyasaram, Eleanor Harris, Tiffany Hodges, Lindsay Ferguson, Serah Choi
Journal: Journal of the National Comprehensive Cancer Network (2022)
EVALUATION OF THE PATTERNS LEADING TO DIAGNOSIS IN PATIENTS WITH AMYLOID LIGHT-CHAIN AMYLOIDOSIS USING THE KOMODO DATABASE
Authors: Julia N. Catini, Quan Doan, Jennifer Evans, Bonny Shah, Andrew Rava, anusorn thanataveerat, Thomas Defay, Guillermo del Angel, Megan Teynor, Candida Cristina Quarta
Journal: Journal of the American College of Cardiology (2022)
RISK FACTORS ASSOCIATED WITH 60-DAY MORTALITY FOLLOWING CARDIAC LEAD EXTRACTION
Authors: Robert Derenbecker, Chad Colon, James Barrios, Pankaj Arora, Vibhu Parcha, Siva Krothapalli, Ruchit Shah, Vance John Plumb, Harish Doppalapudi, Hugh T. McElderry, William R. Maddox
Journal: Journal of the American College of Cardiology (2022)
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
Authors: Adrien Picod, Jean-Michel Rebibou, Antoine Dossier, Bérengère Cador, David Ribes, Claire Vasco-Moynet, Caroline Stephan, Mathieu Bellal, Alain Wynckel, Pascale Poullin, Edwige Péju, Laure Ricard, Jean-Emmanuel Kahn, Raïda Bouzid, Ygal Benhamou, Bérangère Joly, Agnès Veyradier, Paul Coppo
Journal: Blood (2022)
Abstract ES8-1: Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed
Authors: H Sbitany
Journal: Cancer Research (2022)

Abstract Upper extremity lymphedema following axillary lymph node harvest or radiation therapy, can be extremely debilitating and symptomatic in breast cancer patients, and significantly reduces quality of life. In recent years, surgical procedures to reduce the development and progression of lymphedema have become more prevalent. These surgical procedures carry the aim of restoring lymphatic flow in the extremity following disruption of native channels. The most common procedures include vascularized lymph node transfer (VLNT) to the axilla, and lymphaticovenous bypass (LV bypass). The goal of both procedures is to restore flow, and reduce symptoms (infections, cellulitis, and reduced range of motion). VLNT involves harvest and transfer of autologous lymph node packets from a separate area of the body (most frequently the groin or supraclavicular region), and placement into the involved axilla, followed by microsurgical revascularization of the lymph nodes. Through cell signaling, this allows development of new lymphatic channel pathways, and resumption of drainage. LV bypass involves localized microsurgical anastomosis of lymphatic channels in the downstream affected extremity, directly to superficial veins in their vicinity. This allows lymphatic channels, proximal to the site of obstruction, to still drain their collected lymphatic fluid, directly into the systemic venous circulation in the extremity. In most cases, multiple LV bypass anastomoses are performed, to enhance lymphatic outflow. Due to the safety and efficacy of both procedures, they continue to be incorporated more frequently and routinely as part of breast reconstruction treatment plans. Citation Format: H Sbitany. Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES8-1.
Transforming growth factor–β1 in regulatory T cell biology
Authors: Joshua M. Moreau, Maria Velegraki, Chelsea Bolyard, Michael D. Rosenblum, Zihai Li
Journal: Science Immunology (2022)

Transforming growth factor-β1 (TGF-β1) is inextricably linked to regulatory T cell (Treg) biology. However, precisely untangling the role for TGF-β1 in Treg differentiation and function is complicated by the pleiotropic and context-dependent activity of this cytokine and the multifaceted biology of Tregs. Among CD4+ T cells, Tregs are the major producers of latent TGF-β1 and are uniquely able to activate this cytokine via expression of cell surface docking receptor glycoprotein A repetitions predominant (GARP) and αv integrins. Although a preponderance of evidence indicates no essential roles for Treg-derived TGF-β1 in Treg immunosuppression, TGF-β1 signaling is crucial for Treg development in the thymus and periphery. Furthermore, active TGF-β1 instructs the differentiation of other T cell subsets, including TH17 cells. Here, we will review TGF-β1 signaling in Treg development and function and discuss knowledge gaps, future research, and the TGF-β1/Treg axis in the context of cancer immunotherapy and fibrosis.
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Authors: Stephen J. Nicholls, Yu Kataoka, Steven E. Nissen, Francesco Prati, Stephan Windecker, Rishi Puri, Thomas Hucko, Daniel Aradi, Jean-Paul R. Herrman, Renicus S. Hermanides, Bei Wang, Huei Wang, Julie Butters, Giuseppe Di Giovanni, Stephen Jones, Gianluca Pompili, Peter J. Psaltis
Journal: JACC. Cardiovascular imaging (2022)
Expert Perspective: Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Authors: Naomi J. Patel, John H. Stone
Journal: Arthritis & Rheumatology (2022)

The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise a major subset of diseases that cause destructive inflammation of small and medium-sized blood vessels. Although these conditions have a predilection for pulmonary and renal involvement, they are in fact protean diseases that can involve essentially any organ system. AAV is among the most difficult rheumatic diseases to diagnose and treat. Therapy for AAV has evolved over the past two decades. Rituximab, an anti-CD20 monoclonal antibody, is now the preferred agent for remission induction in conjunction with a reduced-dose glucocorticoid taper. Rituximab is also often a key therapy for remission maintenance. Glucocorticoid toxicity reduction has become a major priority for treatment regimens. Avacopan, an important new adjunct to remission induction therapy, may reduce glucocorticoid use and its resulting toxicity. The role of avacopan as a remission maintenance agent requires further study. The duration of immunosuppression following remission is guided by a number of factors, including the patient's overall clinical state, the degree of damage from previous disease activity, the tolerability of remission maintenance medications, and SARS-CoV-2 vaccination and immunity status. Certain features, including history of previous relapse, the presence of ANCA directed against proteinase 3, and a diagnosis of granulomatosis with polyangiitis, favor prolonged remission maintenance therapy. The interval between rituximab doses can usually be lengthened over time during the maintenance phase.
CHARACTERIZING ACUTE CARE CARDIOLOGY CENTRAL VENOUS CATHETER USE AND ASSOCIATED COMPLICATIONS
Authors: Megan Rodts, Colleen Pater, Sonali S. Patel, Lara Khadr, Margaret Graupe, Julie Bushnell, Emmanuelle Favilla, Mary Howell, Susan Schachtner, Adam Ware, Nicolas Madsen
Journal: Journal of the American College of Cardiology (2022)
CLINICAL CHARACTERISTICS, EVALUATION AND OUTCOMES OF CHYLOPERICARDIUM: A SYSTEMATIC REVIEW
Authors: Beni Verma, Ashwin Kumar, Nikita Verma, Ankit Agrawal, Abdullah Yesilyaprak, Muhammad Furqan, Gauranga Mahalwar, Pejman Raeisi-Giglou, Mary Schleicher, Mohamed Nasser, Tom Wang, Allan L. Klein
Journal: Journal of the American College of Cardiology (2022)